CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
28 01 2021
Historique:
received: 04 09 2020
accepted: 12 10 2020
pubmed: 23 10 2020
medline: 13 5 2021
entrez: 22 10 2020
Statut: epublish

Résumé

Toward development of a dual vaccine for human immunodeficiency virus type 1 (HIV-1) and tuberculosis infections, we developed a urease-deficient bacillus Calmette-Guérin (BCG) strain Tokyo172 (BCGΔurease) to enhance its immunogenicity. BCGΔurease expressing a simian immunodeficiency virus (SIV) Gag induced BCG antigen-specific CD4

Identifiants

pubmed: 33087465
pii: JVI.01718-20
doi: 10.1128/JVI.01718-20
pmc: PMC7851566
pii:
doi:

Substances chimiques

AIDS Vaccines 0
BCG Vaccine 0
SAIDS Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 Kato et al.

Références

Vaccine. 2014 Feb 7;32(7):839-45
pubmed: 24370703
Nature. 2012 Nov 15;491(7424):406-12
pubmed: 23151583
Immunogenetics. 2012 Feb;64(2):131-41
pubmed: 21881951
Microbes Infect. 2006 May;8(6):1539-49
pubmed: 16702011
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7
pubmed: 15753319
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
pubmed: 23100539
N Engl J Med. 2013 Jun 6;368(23):2210-8
pubmed: 23738546
Infect Immun. 1996 Jan;64(1):1-9
pubmed: 8557324
Immunity. 2008 Dec 19;29(6):1009-21
pubmed: 19062316
FEMS Immunol Med Microbiol. 2008 Jun;53(1):96-106
pubmed: 18400013
Nature. 2002 Jan 17;415(6869):331-5
pubmed: 11797011
J Virol. 1992 Apr;66(4):2067-75
pubmed: 1548752
Immunogenetics. 2010 Sep;62(9):601-11
pubmed: 20640416
Genes Cells. 1996 Jun;1(6):569-79
pubmed: 9078386
J Virol. 2005 Jul;79(14):8878-85
pubmed: 15994781
Nat Med. 2012 Nov;18(11):1673-81
pubmed: 22961108
Nat Med. 2009 Mar;15(3):293-9
pubmed: 19219024
PLoS One. 2012;7(12):e51633
pubmed: 23236521
Nature. 2011 May 26;473(7348):523-7
pubmed: 21562493
Vaccine. 2013 Aug 2;31(35):3549-57
pubmed: 23731631
J Virol. 2007 Nov;81(21):11640-9
pubmed: 17728225
J Virol. 2005 Jul;79(14):8716-23
pubmed: 15994765
Vaccines (Basel). 2014 Oct 17;2(4):755-71
pubmed: 26344890
Virology. 2007 Jan 20;357(2):186-98
pubmed: 16996101
J Virol. 2013 May;87(10):5424-36
pubmed: 23468483
Front Immunol. 2017 Sep 19;8:1147
pubmed: 28974949
J Virol. 1998 Apr;72(4):2855-64
pubmed: 9525605
Nat Med. 2016 Jul;22(7):762-70
pubmed: 27239761
J Immunol Methods. 2011 Mar 7;366(1-2):8-19
pubmed: 21192942
Vaccine. 2009 Feb 11;27(7):966-71
pubmed: 19135118
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
J Gen Virol. 2016 Dec;97(12):3413-3426
pubmed: 27902330
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
J Virol. 2013 Feb;87(3):1708-19
pubmed: 23175374
Sci Transl Med. 2011 May 4;3(81):81ra36
pubmed: 21543722
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
J Infect Dis. 2011 Nov;204(9):1395-402
pubmed: 21921208
J Virol. 2000 Jul;74(14):6564-9
pubmed: 10864670
N Engl J Med. 2018 Jul 12;379(2):138-149
pubmed: 29996082
Nat Med. 2019 Feb;25(2):255-262
pubmed: 30664782
Vaccine. 2006 Nov 17;24(47-48):7009-22
pubmed: 17052815
Infect Immun. 1987 Jun;55(6):1466-75
pubmed: 3553003
J Virol. 2012 Nov;86(22):12039-52
pubmed: 22933282
Science. 2008 Jul 25;321(5888):530-2
pubmed: 18653883
Virology. 2010 Mar 30;399(1):134-143
pubmed: 20102777
Wkly Epidemiol Rec. 2010 Jan 29;85(5):29-33
pubmed: 20151491
FEMS Microbiol Lett. 1996 Jan 15;135(2-3):237-43
pubmed: 8595863
Clin Vaccine Immunol. 2014 Oct;21(10):1385-95
pubmed: 25080550
J Infect Dis. 2017 Jan 1;215(1):95-104
pubmed: 28077588
Nat Commun. 2019 May 21;10(1):2257
pubmed: 31113957
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233

Auteurs

Seiichi Kato (S)

Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan.
Research & Development Department, Japan BCG Laboratory, Tokyo, Japan.

Hisatoshi Shida (H)

Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan hmyy2010@yahoo.co.jp matsuo@bcg.gr.jp.
Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.

Tomotaka Okamura (T)

Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan.

Xianfeng Zhang (X)

Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Tomoyuki Miura (T)

Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.

Tetsu Mukai (T)

Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Makoto Inoue (M)

ID Pharma Co., Ltd., Ibaraki, Japan.

Tsugumine Shu (T)

ID Pharma Co., Ltd., Ibaraki, Japan.

Taeko K Naruse (TK)

Tokyo Medical and Dental University, Tokyo, Japan.
Department of Immunogenetics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.

Akinori Kimura (A)

Tokyo Medical and Dental University, Tokyo, Japan.

Yasuhiro Yasutomi (Y)

Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan.

Kazuhiro Matsuo (K)

Research & Development Department, Japan BCG Laboratory, Tokyo, Japan hmyy2010@yahoo.co.jp matsuo@bcg.gr.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH